With ZEJULA, You Have a Choice About What Comes Next in Your Ovarian Cancer Treatment
ZEJULA is a once-daily oral medicine used for the maintenance treatment of women with recurrent ovarian, fallopian tube, or primary peritoneal cancer when their cancer comes back.
ZEJULA is the first and only once-daily PARP inhibitor used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy.1-3
See below for full Indication.
ZEJULA was evaluated as a maintenance treatment in a double-blind, placebo-controlled phase 3 trial of 553 women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who1*
- Received at least 2 platinum-based chemotherapy treatments, and
- Had a complete or partial response to the most recent chemotherapy
The study was designed to measure how long women lived with epithelial ovarian, fallopian tube, or primary peritoneal cancer without their disease getting worse. The treatment benefit of ZEJULA was independently tested in women with the BRCA gene and women without the BRCA gene.1
*65 women who were BRCA-positive received a placebo (eg, sugar pill), and 116 women who were BRCA-negative received a placebo.
Get more information about what ovarian cancer recurrence might mean for youUnderstand Recurrent Ovarian Cancer
Learn how ZEJULA may extend your time in responseLearn about ZEJULA
Find resources that may help you access and pay for ZEJULAGet Access and Support